LUNG CANCER How much platinum-based chemotherapy is enough in NSCLC?

被引：5
|
作者：
Peters, Solange [1 ]
Adjei, Alex A. [2 ]
机构：
[1] CHU Vaudois, Dept Oncol, CH-1011 Lausanne, Switzerland
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2015年 / 12卷 / 01期
关键词：
PHASE-III; RANDOMIZED TRIAL; METAANALYSIS; CISPLATIN; SURVIVAL; DURATION; COURSES; CYCLES;
D O I：
10.1038/nrclinonc.2014.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
With no large randomized phase III trials to provide definitive answers, the ideal number of platinum-based chemotherapy cycles in patients with advanced non-small-cell lung cancer has long been unclear. Most guidelines recommend a maximum of 4-6 cycles. Rossi and colleagues now suggest that four chemotherapy cycles is the optimal regimen.
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [31] INTRINSIC AND ACQUIRED RESISTANCE PATTERNS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
    Stewart, David J.
    Saintigny, Pierre
    Lu, Charles
    Goss, Glenwood
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S862 - S863
  • [32] Adjuvant chemotherapy: how much is enough?
    O'Regan, Ruth M.
    LANCET ONCOLOGY, 2009, 10 (12): : 1132 - 1133
  • [33] Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC)
    Costa, Guilherme Jorge
    Godoy Fernandes, Ana Luisa
    Pereira, Jose Rodrigues
    Curtis, J. Randall
    Santoro, Ilka Lopes
    LUNG CANCER, 2006, 53 (02) : 171 - 176
  • [34] Sintilimab plus platinum-based chemotherapy for non-squamous NSCLC
    Venkatesan, Priya
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E76 - E76
  • [35] Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine
    Yin, Ji-Ye
    Li, Xi
    Zhou, Hong-Hao
    Liu, Zhao-Qian
    PHARMACOGENOMICS, 2016, 17 (12) : 1365 - 1378
  • [36] EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy
    Shah, Manan P.
    Aredo, Jacqueline, V
    Padda, Sukhmani K.
    Ramchandran, Kavitha J.
    Wakelee, Heather A.
    Das, Millie S.
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2022, 23 (02) : E148 - E153
  • [37] Thromboembolic events (TE) in patients with meta-static non small cell lung cancer (NSCLC) treated with platinum-based chemotherapy
    Castellon-Rubio, V
    Canosa-Ruiz, L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 77 - 77
  • [38] The Feasibility of Platinum-based Combination Chemotherapy for Advanced Lung Cancer With Idiopathic Interstitial Pneumonias
    Minegishi, Y.
    Gemma, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S624 - S624
  • [39] Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)
    Noroxe, Dorte Schou
    Wallerek, Sandra
    Sorensen, Jens Benn
    ANTICANCER RESEARCH, 2013, 33 (08) : 3275 - 3278
  • [40] HOW MUCH LUNG IS GOOD ENOUGH
    WEIBEL, ER
    EUROPEAN JOURNAL OF RESPIRATORY DISEASES, 1986, 69 : 37 - 45
12345